Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Fourth phase III study shows Herceptin plus chemo improved disease-free survival
October 13th, 2005
Genentech, Inc., (DNA) announced that a planned interim analysis of a phase III trial of Herceptin (Trastuzumab) plus chemotherapy in the adjuvant setting showed a significant reduction in the risk of disease recurrence in women with early-stage (or cancer that has not spread beyond the breast and associated lymph nodes) human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The international study was supported by sanofi-aventis and Genentech, and conducted by the Breast Cancer International Research Group (BCIRG). The trial evaluated three regimens as adjuvant therapy following initial treatment with surgery: 1)...
Source: Women's Health Weekly (2005-10-13)
|
